Genmab — December 2020

[Vitus]

Er de ikke forlængst offentliggjort ??

[Doublo]

Det kan godt være det er mig der misforstår det, hvor tit kommer der recepttal?

[Doublo]

Tak for oplysningen

[Doublo]

Mon det er dollar kursen der driller, det ser godt nok kedeligt ud, ikke mange kunder til Genmab i dag. Jeg solgte en del Vestas i går for at købe flere Genmab, det var vist ikke lige så heldigt.

[Doublo]

Læser i Børsen, at Genmab får beslaglagt en fabrik i USA, da den skal bruges til vaccinefremstilling!!!

[Solsen]

Det er Horizon der er ramt. Genmab kan nok ikke regne med royalty på Tapezza i Q121.

[E_L]

Janssen Announces Health Canada Approval of DARZALEX* Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma - VTd- CASSIOPEIA -https://finance.yahoo.com/finance/news/now-open-experience-sky-high-130500836.html

[E_L]

Changes in Biologics Dosing May Help Keep Patients Safe From COVID-19 https://www.targetedonc.com/view/changes-in-biologics-dosing-may-help-keep-patients-safe-from-covid-19

[bibob]

God morgen og god lillejuleaftens morgen.

[bibob]

OncLive. https://www.onclive.com/view/should-all-elderly-patients-with-newly-diagnosed-multiple-myeloma-receive-monoclonal-antibodies-?utm_source=sfmc&utm_medium=email&utm_campaign=12-22-20_CEL-20-OGD0756_OncLiveSS_Multiple Myeloma CC eNews_Revlimid, Celgene_NON_US_Send&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Onsdagens danske avisuddrag med prisfest, ISS og vaccinepas
https://www.proinvestor.com/investornyt/670613/onsdagens-danske-avisuddrag-med-prisfest-iss-og-vaccinepas

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

Summary points from expert feedback:

Preliminary efficacy for BCMA-directed bispecifics ranging from 60% to 80% looks very promising
Risk/benefit profiles not mature enough to identify distinguishing features but too soon to rule out Amgen’s AMG 701 based on early safety data

[Sukkeralf]

KOL sees bispecifics quickly being moving up as part of combinations as far as first relapse, and eventually perhaps even into first-line treatment
Anti-BCMA CAR-T cells will have an initial first-to-market advantage but bispecifics’ ease of use should give them a leg up, especially in the community
Candidates addressing novel targets like FcRH5 and GPCR5D look highly promising for BCMA-experienced patients

[E_L]

Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis https://www.frontiersin.org/articles/10.3389/fneur.2020.602102/full

[Bulder]

Thx Sugar and E L. Looks good for both T&T and dara.

[Helge_LarsenPI-redaktør]

November Darzalex US salg $ 237M. (November havde 19 arbejdsdage mod 21 i oktober).

[Doublo]

Er salget godt

[Bulder]

Det er en lille stigning. 12,47$/dag i nov mod 11,31$ i okt.